{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:41:19Z","timestamp":1794274879024,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioma remains a highly aggressive malignancy with frequent recurrence and resistance to radiotherapy and chemotherapy. BTN3A2 is a multifunctional regulatory protein originally implicated in \u03b3\u03b4 T-cell\u2013mediated immune responses, yet its tumor-intrinsic role and mechanistic relevance in glioma are poorly defined. Here, BTN3A2 expression and prognostic associations were assessed in TCGA and CGGA cohorts and further validated by immunohistochemistry on tissue microarrays. Functional studies using lentivirus-mediated BTN3A2 knockdown demonstrated that BTN3A2 promotes glioma cell proliferation, migration, and invasion, and its depletion increases TMZ sensitivity in vitro and in vivo. Mechanistically, integrated RNA-seq, CUT&amp;Tag, and promoter luciferase assays identified BTN3A2 as a hypoxia-responsive gene directly transcriptionally activated by HIF-1\u03b1. BTN3A2 subsequently enhanced DNA damage repair capacity through activation of the AKT\/SP1\/RAD51 axis, thereby contributing to TMZ resistance. Collectively, these findings establish BTN3A2 as a hypoxia-driven, cell-intrinsic mediator of glioma progression and chemoresistance, highlighting its potential value as a prognostic biomarker and therapeutic vulnerability.<\/jats:p>","DOI":"10.1038\/s41419-026-08729-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:27:11Z","timestamp":1775906831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypoxia-induced BTN3A2 promotes glioma progression and chemoresistance via AKT\/SP1\/RAD51-mediated DNA damage"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-776X","authenticated-orcid":false,"given":"Zhixing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanrui","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7331-1890","authenticated-orcid":false,"given":"Fengcai","family":"shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1126-3118","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2938-2406","authenticated-orcid":false,"given":"Jun","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"8729_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021. Neuro Oncol. 2024;26:vi1\u2013vi85.","journal-title":"Neuro Oncol"},{"key":"8729_CR2","doi-asserted-by":"publisher","first-page":"2318506","DOI":"10.1080\/15592294.2024.2318506","volume":"19","author":"S Ma","year":"2024","unstructured":"Ma S, Pan X, Gan J, Guo X, He J, Hu H, et al. DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma. EPIGENETICS-US. 2024;19:2318506.","journal-title":"EPIGENETICS-US"},{"key":"8729_CR3","doi-asserted-by":"crossref","unstructured":"Mangena V, Chanoch-Myers R, Sartore R, Paulsen B, Gritsch S, Weisman H, et al. Glioblastoma-cortical organoids recapitulate cell-state heterogeneity and intercellular transfer. Cancer Discov. 2025;15:299\u2013315.","DOI":"10.1158\/2159-8290.CD-23-1336"},{"key":"8729_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11060-022-04090-9","volume":"159","author":"S Onishi","year":"2022","unstructured":"Onishi S, Yamasaki F, Amatya VJ, Takayasu T, Yonezawa U, Taguchi A, et al. Characteristics and therapeutic strategies of radiation-induced glioma: case series and comprehensive literature review. J Neurooncol. 2022;159:531\u20138.","journal-title":"J Neurooncol"},{"key":"8729_CR5","first-page":"673.","volume":"14","author":"D Smerdi","year":"2024","unstructured":"Smerdi D, Moutafi M, Kotsantis I, Stavrinou LC, Psyrri A. Overcoming Resistance to Temozolomide in Glioblastoma: A Scoping Review of Preclinical and Clinical Data. Life (Basel). 2024;14:673.","journal-title":"Life (Basel)"},{"key":"8729_CR6","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.1021\/jm401121k","volume":"56","author":"D Pletsas","year":"2013","unstructured":"Pletsas D, Garelnabi EA, Li L, Phillips RM, Wheelhouse RT. Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53 [J]. J Med Chem. 2013;56:7120\u201332.","journal-title":"J Med Chem"},{"key":"8729_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/1878-0261.13020","volume":"16","author":"O Rominiyi","year":"2022","unstructured":"Rominiyi O, Collis SJ. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. Mol Oncol. 2022;16:11\u201341.","journal-title":"Mol Oncol"},{"key":"8729_CR8","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.7150\/thno.26225","volume":"8","author":"L Hua","year":"2018","unstructured":"Hua L, Wang Z, Zhao L, Mao H, Wang G, Zhang K, et al. Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy. Theranostics. 2018;8:5088\u2013105.","journal-title":"Theranostics"},{"key":"8729_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.203","volume":"4","author":"Y Zhuang","year":"2023","unstructured":"Zhuang Y, Liu K, He Q, Gu X, Jiang C, Wu J. Hypoxia signaling in cancer: Implications for therapeutic interventions. MedComm. 2023;4:e203.","journal-title":"MedComm"},{"key":"8729_CR10","first-page":"42.","volume":"7","author":"M Rigau","year":"2021","unstructured":"Rigau M, Uldrich AP, Behren A. Targeting butyrophilins for cancer immunotherapy. TRENDS IMMUNOL. 2021;7:42.","journal-title":"TRENDS IMMUNOL"},{"key":"8729_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00251-012-0619-z","volume":"64","author":"H Afrache","year":"2012","unstructured":"Afrache H, Gouret P, Ainouche S, Pontarotti P, Olive D. The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response. Immunogenet ics. 2012;64:781\u201394.","journal-title":"Immunogenet ics"},{"key":"8729_CR12","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1002\/eji.200425227","volume":"34","author":"E Compte","year":"2004","unstructured":"Compte E, Pontarotti P, Collette Y, Lopez M, Olive D. Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J I mmunol. 2004;34:2089\u201399.","journal-title":"Eur J I mmunol"},{"key":"8729_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/cells9040829","volume":"9","author":"KP K\u00fcnkele","year":"2020","unstructured":"K\u00fcnkele KP, Wesch D, Oberg HH, Aichinger M, Supper V, Baumann C. V\u03b39V\u03b42 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy? Cells. 2020;9:829 Mar 30.","journal-title":"Cells"},{"key":"8729_CR14","doi-asserted-by":"crossref","unstructured":"Kone AS, Ait Ssi S, Sahraoui S, Badou A. BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment. Int J Mol Sci. 2022;23:13424.","DOI":"10.3390\/ijms232113424"},{"key":"8729_CR15","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.7150\/jca.57831","volume":"12","author":"S Chen","year":"2021","unstructured":"Chen S, Li Z, Huang W, Wang Y, Fan S. Prognostic and Therapeutic Significance of BTN3A Proteins in Tumors. J Cancer. 2021;12:4505\u201312.","journal-title":"J Cancer"},{"key":"8729_CR16","doi-asserted-by":"publisher","first-page":"eabj0835","DOI":"10.1126\/scitranslmed.abj0835","volume":"13","author":"A De Gassart","year":"2021","unstructured":"De Gassart A, Le KS, Brune P, Agaugu\u00e9 S, Sims J, Goubard A, et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response. Sci Transl Med. 2021;13:eabj0835.","journal-title":"Sci Transl Med"},{"key":"8729_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/JLB.5MA0321-158RR","volume":"110","author":"H Ren","year":"2021","unstructured":"Ren H, Li S, Liu X, Li W, Hao J, Zhao N. Multi-omics analysis of the expression and prognostic value of the butyrophilins in breast cancer. Journal of leukocyte biology. 2021;110:1181\u201395.","journal-title":"Journal of leukocyte biology"},{"key":"8729_CR18","doi-asserted-by":"publisher","first-page":"e1372080.","DOI":"10.1080\/2162402X.2017.1372080","volume":"7","author":"A Benyamine","year":"2017","unstructured":"Benyamine A, Loncle C, Foucher E, Blazquez JL, Castanier C, Chr\u00e9tien AS, et al. BTN3A is a prognosis marker and a promising target for V\u03b39V\u03b42 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Oncoimmunology. 2017;7:e1372080.","journal-title":"Oncoimmunology"},{"key":"8729_CR19","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"8729_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/neuonc\/not010","volume":"15","author":"L Cen","year":"2013","unstructured":"Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, et al. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro Oncol. 2013;15:735\u201346.","journal-title":"Neuro Oncol"},{"key":"8729_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","volume":"11","author":"GJ Kitange","year":"2009","unstructured":"Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11:281\u201391.","journal-title":"Neuro Oncol"},{"key":"8729_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1158\/1535-7163.MCT-08-0854","volume":"8","author":"MJ Clarke","year":"2009","unstructured":"Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther. 2009;8:407\u201314.","journal-title":"Mol Cancer Ther"},{"key":"8729_CR23","first-page":"189244","volume":"1880","author":"H Branco","year":"2025","unstructured":"Branco H, Xavier CPR, Riganti C, Vasconcelos MH. Hypoxia as a critical player in extracellular vesicles-mediated intercellular communication between tumor cells and their surrounding microenvironment. BBA-REV CANCER. 2025;1880:189244.","journal-title":"BBA-REV CANCER"},{"key":"8729_CR24","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.3390\/ijms25126690","volume":"25","author":"J Wang","year":"2024","unstructured":"Wang J, Song X, Wei M, Qin L, Zhu Q, Wang S, et al. PCAS: An Integrated Tool for Multi-Dimensional Cancer Research Utilizing Clinical Proteomic Tumor Analysis Consortium Data. International Journal of Molecular Sciences. 2024;25:6690.","journal-title":"International Journal of Molecular Sciences"},{"key":"8729_CR25","doi-asserted-by":"crossref","unstructured":"Zapanta Rinonos S, Li T, Pianka ST, Prins TJ, Eldred BSC, Kevan BM dCas9\/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. J Neuro-Oncol.166, 129-42.","DOI":"10.1007\/s11060-023-04531-z"},{"key":"8729_CR26","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","volume":"120","author":"C Harly","year":"2012","unstructured":"Harly C, Guillaume Y, Nedellec S, Peign\u00e9 CM, M\u00f6nkk\u00f6nen H, M\u00f6nkk\u00f6nen J, et al. Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset. BLOOD. 2012;120:2269\u201379.","journal-title":"BLOOD"},{"key":"8729_CR27","doi-asserted-by":"publisher","first-page":"e38541","DOI":"10.1371\/journal.pone.0038541","volume":"7","author":"C Le Page","year":"2012","unstructured":"Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, et al. BTN3A2 expression in epit helial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One. 2012;7:e38541.","journal-title":"PLoS One"},{"key":"8729_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/0008-5472.CAN-16-1647","volume":"77","author":"S Lim","year":"2017","unstructured":"Lim S, Phillips JB, Madeira da Silva L, Zhou M, Fodstad O, Owen LB, et al. Interplay between Immune Checkpoint Proteins and Cellular Metabolism. Cancer Res. 2017;77:1245\u20139.","journal-title":"Cancer Res"},{"key":"8729_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25\u201339.","journal-title":"Nat Rev Immunol"},{"key":"8729_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13046-025-03514-4","volume":"44","author":"OJ Hussein","year":"2025","unstructured":"Hussein OJ, Rayan M, Matarid TR, Elkhalifa D, Abunada HH, Therachiyil L, et al. The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy. J Exp Clin Cancer Res. 2025;44:305.","journal-title":"J Exp Clin Cancer Res"},{"key":"8729_CR31","doi-asserted-by":"crossref","unstructured":"Begagi\u0107 E, Be\u010duli\u0107 H, D\u017eidi\u0107-Krivi\u0107 A, Kadi\u0107 Vukas S, Had\u017ei\u0107 S, Meki\u0107-Abazovi\u0107 A, et al. Understanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review. Cancers (Basel). 2024;16:2089.","DOI":"10.3390\/cancers16112089"},{"key":"8729_CR32","doi-asserted-by":"publisher","first-page":"e0315171","DOI":"10.1371\/journal.pone.0315171","volume":"20","author":"A Berezovsky","year":"2025","unstructured":"Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K, et al. Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment. PLoS One. 2025;20:e0315171.","journal-title":"PLoS One"},{"key":"8729_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrc3972","volume":"15","author":"RM Hoffman","year":"2015","unstructured":"Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015;15:451\u20132.","journal-title":"Nat Rev Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08729-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:16:08Z","timestamp":1779074168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08729-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8729"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08729-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The human glioma tissue microarray used for immunohistochemistry was commercially purchased from Shanghai Outdo Biotechnology Co., Ltd. (Product No. HBraG159Su01). The use of the human tissue microarray was reviewed and approved by the Ethics Committee of Shanghai Outdo Biotech Company (Approval No. SHYJS-CP-1801020). All human specimens were de-identified before being provided to the authors, and informed consent was obtained from all participants by the tissue provider prior to sample collection. No identifiable personal information was available to the authors. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Second Affiliated Hospital of Kunming Medical University (Approval No. kyfey2023084) and were performed in accordance with the institutional guidelines for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"469"}}